Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2012

View Archived Issues

Novel TTK inhibitors patented by Bayer Schering Pharma

Array BioPharma synthesizes novel kinase inhibitors

Allergan patents new CCR2 receptor antagonists

Novel protein kinase inhibitors disclosed by Roche

German researchers present new GPR119 receptor agonists

Abbott designs new potential hepatitis therapies

AbOs-targeted antibodies show potential in Alzheimer's disease model

Abbott halts development of two clinical-stage candidate drugs for Alzheimer's disease

New AHA/ACC guideline update includes ticagrelor

New candidate biomarker for prostate cancer discovered

Eisai and Verastem enter research collaboration

AstraZeneca plans to evaluate ticagrelor in patients with PAD

Oncolytic virus research collaboration begins for bladder cancer

Phase II results presented on insulin analogue for diabetes

German authorities approve SkyePharma's asthma product

FDA advisory committee to discuss NDAs for Novo Nordisk insulin products

FDA approves VIVUS drug for weight management

U.S. scientists develop new model of early-onset Alzheimer's disease

Orphan medicinal product designation granted for levoglutamide

Janssen seeks U.S. and E.U. approval for Simponi

Grifols to conduct safety study of inhaled alpha1-proteinase inhibitor

Medgenics commences Israeli study of Epodure Biopumps

Isotechnika receives further funding from Canadian government

Nymox provides update on pivotal U.S. phase III trials in BPH

Antisense Therapeutics executes agreement for ATL-1102

FDA grants orphan drug status to antibody-drug conjugate in mesothelioma

Soligenix receives grant for acute radiation syndrome therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...